Esperion Therapeutics (ESPR) Competitors $2.57 -0.52 (-16.83%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$2.65 +0.08 (+3.11%) As of 04:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. BLTE, GLPG, CDTX, IDYA, IRON, RXRX, BHC, IBRX, AGIO, and ARQTShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Belite Bio (BLTE), Galapagos (GLPG), Cidara Therapeutics (CDTX), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Recursion Pharmaceuticals (RXRX), Bausch Health Cos (BHC), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Its Competitors Belite Bio Galapagos Cidara Therapeutics IDEAYA Biosciences Disc Medicine Recursion Pharmaceuticals Bausch Health Cos ImmunityBio Agios Pharmaceuticals Arcutis Biotherapeutics Belite Bio (NASDAQ:BLTE) and Esperion Therapeutics (NASDAQ:ESPR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends. Does the media favor BLTE or ESPR? In the previous week, Esperion Therapeutics had 8 more articles in the media than Belite Bio. MarketBeat recorded 10 mentions for Esperion Therapeutics and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.80 beat Esperion Therapeutics' score of 0.32 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Esperion Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BLTE or ESPR more profitable? Belite Bio has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -35.84%. Esperion Therapeutics' return on equity of 0.00% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Belite BioN/A -34.90% -33.56% Esperion Therapeutics -35.84%N/A -28.41% Which has preferable valuation & earnings, BLTE or ESPR? Belite Bio has higher earnings, but lower revenue than Esperion Therapeutics. Belite Bio is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelite BioN/AN/A-$36.14M-$1.55-50.36Esperion Therapeutics$332.31M1.56-$51.74M-$0.49-5.24 Do analysts rate BLTE or ESPR? Belite Bio presently has a consensus price target of $96.00, indicating a potential upside of 22.98%. Esperion Therapeutics has a consensus price target of $7.00, indicating a potential upside of 172.37%. Given Esperion Therapeutics' higher probable upside, analysts plainly believe Esperion Therapeutics is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals believe in BLTE or ESPR? 0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 1.7% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, BLTE or ESPR? Belite Bio has a beta of -1.46, meaning that its stock price is 246% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. SummaryEsperion Therapeutics beats Belite Bio on 9 of the 13 factors compared between the two stocks. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$623.02M$2.64B$6.10B$10.55BDividend YieldN/A56.71%5.69%4.75%P/E Ratio-5.2423.6985.6027.60Price / Sales1.56556.27538.21205.12Price / Cash128.61173.2337.9261.55Price / Book-1.305.5313.246.76Net Income-$51.74M$32.78M$3.30B$275.88M7 Day Performance-11.38%5.82%4.35%2.81%1 Month Performance1.18%13.16%9.51%9.24%1 Year Performance33.16%1.69%88.04%35.42% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics3.8118 of 5 stars$2.57-16.8%$7.00+172.4%+24.2%$623.02M$332.31M-5.24200Analyst ForecastGap DownHigh Trading VolumeBLTEBelite Bio2.8575 of 5 stars$78.10+3.3%$96.00+22.9%+44.8%$2.49BN/A-50.3910Positive NewsAnalyst ForecastHigh Trading VolumeGLPGGalapagos0.3502 of 5 stars$35.55-5.5%$26.00-26.9%+16.0%$2.48B$275.61M0.001,310Analyst ForecastCDTXCidara Therapeutics4.0887 of 5 stars$96.45-5.4%$122.29+26.8%+819.8%$2.45B$1.27M-8.6790Analyst ForecastIDYAIDEAYA Biosciences4.1611 of 5 stars$27.49-0.5%$43.36+57.7%-13.6%$2.41B$7M-7.2580Analyst ForecastIRONDisc Medicine2.3656 of 5 stars$69.28+2.2%$98.30+41.9%+46.7%$2.41BN/A-15.5030Analyst ForecastRXRXRecursion Pharmaceuticals1.8391 of 5 stars$5.53+0.7%$7.25+31.1%-5.4%$2.40B$58.84M-3.11400News CoverageAnalyst ForecastOptions VolumeBHCBausch Health Cos4.7566 of 5 stars$6.48-3.0%$9.00+38.9%-21.1%$2.40B$9.63B24.9220,700Analyst ForecastIBRXImmunityBio2.6507 of 5 stars$2.53-0.4%$10.75+324.9%-28.1%$2.39B$14.74M-5.27590AGIOAgios Pharmaceuticals4.5192 of 5 stars$40.89+1.0%$56.00+37.0%+5.2%$2.38B$40.88M3.72390Analyst DowngradeARQTArcutis Biotherapeutics1.3742 of 5 stars$19.76-0.8%$19.80+0.2%+119.4%$2.37B$196.54M-26.35150 Related Companies and Tools Related Companies Belite Bio Competitors Galapagos Competitors Cidara Therapeutics Competitors IDEAYA Biosciences Competitors Disc Medicine Competitors Recursion Pharmaceuticals Competitors Bausch Health Cos Competitors ImmunityBio Competitors Agios Pharmaceuticals Competitors Arcutis Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
